---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002679"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:33:58.697534+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PepGen doses first patient in Phase 2 CONNECT1-EDO51 trial for Duchenne muscular dystrophy

## Summary
- First patient dosed in open-label, multiple ascending dose Phase 2 trial of PGN-EDO51 in DMD patients amenable to exon 51 skipping.
- Trial enrolls ~10 male patients aged >=8 years; starting dose 5 mg/kg escalating to 10 mg/kg pending safety.
- Preliminary data from the 5 mg/kg cohort expected mid-2024: safety, exon skipping, and dystrophin production.
- Phase 1 healthy volunteers showed peak exon 51 skipping of 3.8% after single 10 mg/kg dose; 100% had skipping.
- PGN-EDO51 was generally well-tolerated through 15 mg/kg in Phase 1; trial ID NCT06079736.

## SEC filing metadata
- accession: 0000950170-24-002679
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017024002679/0000950170-24-002679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017024002679/pepg-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002679
- JSON: https://secwatch.observer/filing/0000950170-24-002679.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002679.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.